Vyome Holdings Inc（HIND）股票分析

$2.180

+0.010 (+0.46%)收盘时

Loading chart…

High: 2.180
Open: 2.130
VWAP: 2.16
Vol: 4.40K
Mkt Cap: —
Low: 2.130
Amount: 9.53K
EV/EBITDA, TTM: -0.92

Vyome Holdings, Inc. is a clinical-stage healthcare holding company. The Company is focused on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. Its clinical program VT1953 Gel is focused on cancer patients who are suffering from malignant fungating wounds (MFW). Its preclinical development program, VT1908, is a non-steroidal eye drop, which is focused on Uveitis. Its other business unit is focused on offering artificial intelligence (AI)-driven healthcare solutions across mental health and inflammation care, digital therapeutics and psychoneuroimmunology.

AI analysis of Vyome Holdings Inc (HIND)

buy

Vyome Holdings Inc is a good buy right now due to its recent revenue performance and analyst optimism. The company reported a Q1 revenue of $31.59 million, showing stable growth despite challenges, and has a significant analyst price target of $8, indicating a potential upside of over 260% from the current price of $2.21. However, the main risk lies in the company's net loss of approximately $963,000 for Q1 2026, which highlights ongoing financial pressures.

估值指标

The current forward P/E ratio for Vyome Holdings Inc (HIND) is 0.00, compared to its 5-year average forward P/E of -8.15.

Forward P/E

Overvalued

5Y Average P/E

-8.15

Current P/E

0.00

高估

-2.71

低估

-13.60

Forward EV/EBITDA

Undervalued

5Y Average EV/EBITDA

-0.35

Current EV/EBITDA

-0.92

高估

0.04

低估

-0.74

Forward P/S

Overvalued

5Y Average P/S

27.56

Current P/S

60.92

高估

58.01

低估

-2.89

Whales holding HIND

Romulus Capital Management, LLC

+ HoldingHIND

+0.00%

3M Return

事件时间线

2026-08-28 (ET)